Transcatheter Aortic Valve Implantation (TAVI)
Liverpool Heart and Chest Hospital was one of the first NHS hospitals in the UK to provide a Transcatheter Aortic Valve Implantation (TAVI) service.
Aortic stenosis (narrowing of the outflow valve of the heart) is the commonest valve disorder in the UK. It can be the cause of severe cardiac symptoms and even sudden death when severe. Conventionally open heart surgery is used to replace the valve. Transcatheter aortic valve implantation (TAVI) allows the aortic valve to be replaced without the need for open-heart surgery, and is therefore a good option for patients in whom the risks of open-heart surgery are unacceptably high.
There is a well-established TAVI programme at LHCH. Patients are carefully assessed and discussed at a multidisciplinary meeting before being considered for TAVI.
The TAVI program commenced at Liverpool Heart and Chest Hospital in September 2008 using the Edwards Sapein device. A high volume of TAVI procedures have now been performed, with excellent results.
LHCH was the first cardiac unit in the UK to have a purpose built state-of-the-art Hybrid Theatre that allows our team to perform TAVI procedures in the most desirable clinical environment.
The LHCH TAVI Team
The team comprises both Aortic Heart Surgeons and Cardiologists:
Dr Tim Fairbairn (imaging)
TAVI is a highly specialist alternative to surgical valve replacement for people whose aortic stenosis is causing symptoms which, if severe, can be a life limiting and life threatening. Because the procedure is performed in a minimally invasive way, TAVI is particularly used as an intervention to help patients with the worst prognosis where conventional “open heart” aortic valve replacement would carry a very high a risk.
To find out more about the life-saving and life-renewing TAVI service at Liverpool Heart and Chest Hospital please watch the below video of TAVI patient, Fred Whoell.
TAVI Symposium - Resources
Our TAVI team hosted a dedicated TAVI educational event in 2013.
The aim of this meeting was to review the current state-of-art management of patients with severe, degenerative aortic stenosis and focus on which patients should be considered for TAVI and when/how to refer them on to us.
On the day, we reviewed the evidence base for TAVI, reflected upon our TAVI outcomes in line with national/international data and gave an insight in to our MDT process.
Degenerative aortic valve stenosis is the most common form of valvular heart disease in the developed world and yet so many patients are not even considered for any interventional therapy.
The lives of our patients have been utterly transformed by the TAVI procedure and we felt that it was essential that you were fully informed about our TAVI programme, our results so far and our plans for the future.